<DOC>
	<DOC>NCT02441764</DOC>
	<brief_summary>This is a PMS to observe the safety profile of Halaven in normal clinical practice setting.</brief_summary>
	<brief_title>Halaven Post-Marketing Surveillance (PMS)</brief_title>
	<detailed_description />
	<criteria>Participants who are prescribed with Halaven per approved prescribing information of Halaven will be enrolled in the study. This study will be conducted as complete surveillance method; participants who meet the inclusion/exclusion criteria and administrate Halaven for the first time after conclusion of agreement will be enrolled after consent. Participants who meet all of the following criteria will be eligible for inclusion in the study: 1. Participants with following indication: Participants with locally advanced or metastatic breast cancer who have previously received at least two chemotherapeutic regimens which should have included an anthracycline and a taxane. 2. Participants who have verbal or written consent for use of personal and medical information. Investigators will refer to indications regarding inclusion criteria. 1. Hypersensitivity to the active substance or to any of the excipients 2. Breast feeding 3. Pregnancy Investigators will refer to indications and contraindications regarding exclusion criteria.</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>February 2017</verification_date>
	<keyword>Halaven</keyword>
	<keyword>Eribulin Mesylate</keyword>
	<keyword>locally advanced or metastatic breast cancer</keyword>
</DOC>